G Remington

Summary

Affiliation: Centre for Addiction and Mental Health
Country: Canada

Publications

  1. ncbi request reprint Rational pharmacotherapy in early psychosis
    Gary Remington
    Medical Assessment Program for Schizophrenia, Centre for Addiction and Mental Health, 250 College Street, Totonto, Ontario M5T 1R8, Canada
    Br J Psychiatry Suppl 48:s77-84. 2005
  2. doi request reprint Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment
    Gary Remington
    University of Toronto, Toronto, Ontario, Canada
    Expert Rev Neurother 11:589-607. 2011
  3. doi request reprint Clozapine's role in the treatment of first-episode schizophrenia
    Gary Remington
    Department of Psychiatry, University of Toronto, Canada
    Am J Psychiatry 170:146-51. 2013
  4. doi request reprint Tetrabenazine augmentation in treatment-resistant schizophrenia: a 12-week, double-blind, placebo-controlled trial
    Gary Remington
    Department of Psychiatry, University of Toronto, Toronto, Canada
    J Clin Psychopharmacol 32:95-9. 2012
  5. ncbi request reprint SB-277011 GlaxoSmithKline
    G Remington
    Center for Addiction and Mental Health, Toronto, Ontario, Canada
    Curr Opin Investig Drugs 2:946-9. 2001
  6. ncbi request reprint The use of pharmacotherapy in the prodrome of schizophrenia
    Gary Remington
    Department of Psychiatry, University of Toronto, Toronto, Canada
    CNS Spectr 9:579-86. 2004
  7. doi request reprint "Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial
    Gary Remington
    Schizophrenia Program, Centre for Addiction and Mental Health, 250 College St, Toronto, Ontario M5T 1R8, Canada
    J Clin Psychiatry 72:1042-8. 2011
  8. pmc Antipsychotic dosing: how much but also how often?
    Gary Remington
    Faculty of Medicine, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    Schizophr Bull 36:900-3. 2010
  9. doi request reprint Alterations of dopamine and serotonin transmission in schizophrenia
    Gary Remington
    Department of Psychiatry, Faculty of Medicine, University of Toronto, Ontario, Canada
    Prog Brain Res 172:117-40. 2008
  10. ncbi request reprint Tardive dyskinesia: eliminated, forgotten, or overshadowed?
    Gary Remington
    Faculty of Medicine, University of Toronto, Ontario, Canada
    Curr Opin Psychiatry 20:131-7. 2007

Collaborators

Detail Information

Publications77

  1. ncbi request reprint Rational pharmacotherapy in early psychosis
    Gary Remington
    Medical Assessment Program for Schizophrenia, Centre for Addiction and Mental Health, 250 College Street, Totonto, Ontario M5T 1R8, Canada
    Br J Psychiatry Suppl 48:s77-84. 2005
    ..An increased focus in research specific to first-episode schizophrenia has provided a rapidly growing body of evidence that can be directly translated to clinical practice...
  2. doi request reprint Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment
    Gary Remington
    University of Toronto, Toronto, Ontario, Canada
    Expert Rev Neurother 11:589-607. 2011
    ..This shift in thinking has important theoretical implications from the standpoint of etiology and pathophysiology, but also clinically in terms of treatment and drug development...
  3. doi request reprint Clozapine's role in the treatment of first-episode schizophrenia
    Gary Remington
    Department of Psychiatry, University of Toronto, Canada
    Am J Psychiatry 170:146-51. 2013
    ....
  4. doi request reprint Tetrabenazine augmentation in treatment-resistant schizophrenia: a 12-week, double-blind, placebo-controlled trial
    Gary Remington
    Department of Psychiatry, University of Toronto, Toronto, Canada
    J Clin Psychopharmacol 32:95-9. 2012
    ....
  5. ncbi request reprint SB-277011 GlaxoSmithKline
    G Remington
    Center for Addiction and Mental Health, Toronto, Ontario, Canada
    Curr Opin Investig Drugs 2:946-9. 2001
    ....
  6. ncbi request reprint The use of pharmacotherapy in the prodrome of schizophrenia
    Gary Remington
    Department of Psychiatry, University of Toronto, Toronto, Canada
    CNS Spectr 9:579-86. 2004
    ..We now have a limited number of published reports addressing this topic and these are reviewed here...
  7. doi request reprint "Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial
    Gary Remington
    Schizophrenia Program, Centre for Addiction and Mental Health, 250 College St, Toronto, Ontario M5T 1R8, Canada
    J Clin Psychiatry 72:1042-8. 2011
    ..Based on a better understanding of the brain kinetics of antipsychotics, we have proposed a variation of this approach, "extended" dosing, which allows for intermittent but regular dosing...
  8. pmc Antipsychotic dosing: how much but also how often?
    Gary Remington
    Faculty of Medicine, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    Schizophr Bull 36:900-3. 2010
    ..Does this mean we need to (or should) administer antipsychotics at least daily? There is a body of evidence challenging this long-established clinical axiom...
  9. doi request reprint Alterations of dopamine and serotonin transmission in schizophrenia
    Gary Remington
    Department of Psychiatry, Faculty of Medicine, University of Toronto, Ontario, Canada
    Prog Brain Res 172:117-40. 2008
    ..At present, there is particular interest in the 5-HT(1A), 5-HT(2C), 5-HT(6) and 5-HT(7) receptors as the search for improved pharmacological treatments for schizophrenia continues...
  10. ncbi request reprint Tardive dyskinesia: eliminated, forgotten, or overshadowed?
    Gary Remington
    Faculty of Medicine, University of Toronto, Ontario, Canada
    Curr Opin Psychiatry 20:131-7. 2007
    ..The present review focuses on atypical antipsychotics and tardive dyskinesia...
  11. ncbi request reprint The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia
    Gary Remington
    Department of Psychiatry, University of Toronto, Toronto, Canada
    Schizophr Res 90:229-37. 2007
    ..More sophisticated measurement tools such as MEMS may assist us in better understanding how level and pattern of antipsychotic noncompliance, factors that at present remain poorly understood, impact on symptom exacerbation...
  12. ncbi request reprint A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone
    Gary Remington
    Schizophrenia Program, Centre for Addiction and Mental Health, Toronto, Ont M5T 1R8, Canada
    Am J Psychiatry 163:396-401. 2006
    ..The present study used positron emission tomography (PET) to evaluate its dopamine D(2) binding profile at doses of 25, 50, or 75 mg administered every 2 weeks...
  13. pmc Understanding antipsychotic "atypicality": a clinical and pharmacological moving target
    Gary Remington
    Department of Psychiatry, University of Toronto, Centre for Addiction and Mental Health, Toronto, Ont
    J Psychiatry Neurosci 28:275-84. 2003
    ..The precise degree of these differences and the underlying mechanisms remain unclear, however. The direction new antipsychotic development takes will undoubtedly hinge on answers to these questions...
  14. ncbi request reprint Augmentation strategies in clozapine-resistant schizophrenia
    Gary Remington
    Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    CNS Drugs 19:843-72. 2005
    ..A priori, an endpoint needs to be established and the trial discontinued unless results firmly support added benefits...
  15. ncbi request reprint The crossover approach to switching antipsychotics: what is the evidence?
    Gary Remington
    Department of Psychiatry, University of Toronto, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario, Canada M5T 1R8
    Schizophr Res 76:267-72. 2005
    ..The existing data therefore argue against the position that a crossover approach in switching antipsychotics represents a 'safer' means of preventing clinical deterioration during the switch...
  16. ncbi request reprint Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study
    G Remington
    Centre for Addiction and Mental Health, Clarke Division, Toronto, Ontario, Canada
    J Clin Psychopharmacol 21:440-4. 2001
    ..Clomipramine did not seem more effective on a measure of stereotypy, nor was it better tolerated...
  17. doi request reprint Modeling chronic olanzapine exposure using osmotic minipumps: pharmacological limitations
    Gary Remington
    Department of Psychiatry, University of Toronto, Canada
    Pharmacol Biochem Behav 100:86-9. 2011
    ..As well, strategies in dissolving olanzapine to diminish oxidation are discussed...
  18. doi request reprint Progress in defining optimal treatment outcome in schizophrenia
    Gary Remington
    Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
    CNS Drugs 24:9-20. 2010
    ..To this end, the field has now embraced a recovery model that is seen as a process, multidimensional and individualized, rather than dichotomous and symptom driven...
  19. ncbi request reprint Antipsychotic dosing patterns for schizophrenia in three treatment settings
    G Remington
    Department of Psychiatry, University of Toronto, Ontario, Canada
    Psychiatr Serv 52:96-8. 2001
    ..8 mg). A greater proportion of patients at the provincial hospital received conventional antipsychotics than novel antipsychotics or depot antipsychotics, and a greater proportion received more than one antipsychotic...
  20. ncbi request reprint 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation
    S Kapur
    Schizophrenia Division, Clarke Institute of Psychiatry, Toronto, Ont, Canada
    Am J Psychiatry 155:921-8. 1998
    ..The purpose of this study was to investigate olanzapine's binding to the serotonin 5-HT2 and dopamine D2 receptors in schizophrenic patients being treated with clinically relevant doses...
  21. ncbi request reprint A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy
    S Kapur
    Department of Psychiatry, University of Toronto, Ontario
    Arch Gen Psychiatry 57:553-9. 2000
    ..The following study was undertaken to explore these effects across the clinical dose range and relate this information to its clinical profile...
  22. ncbi request reprint Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia
    S Kapur
    Schizophrenia Program, PET Centre, CAMH, Toronto, Department of Psychiatry, University of Toronto, 250 College Street, Toronto, Ontario, Canada M5T 1R8
    Annu Rev Med 52:503-17. 2001
    ..e. positive, negative, cognitive, and affective) with more selective drugs that can be combined and individually titrated to the needs of each patient...
  23. ncbi request reprint PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia
    S Kapur
    Schizophrenia Division, Clarke Institute of Psychiatry, University of Toronto, Canada
    Am J Psychiatry 154:1525-9. 1997
    ..The purpose of this study was to document loxapine's 5-HT2 and D2 receptor occupancy in vivo in patients with psychoses...
  24. ncbi request reprint High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study
    S Kapur
    PET Centre, Clarke Institute of Psychiatry, Toronto, Ont, Canada
    Am J Psychiatry 153:948-50. 1996
    ..The purpose of this study was to determine the dopamine D2 receptor occupancy induced by low-dose haloperidol treatment in a prospective trial...
  25. ncbi request reprint Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia
    S Kapur
    The Clarke Institute of Psychiatry, Department of Psychiatry, University of Toronto, ON, Canada
    Am J Psychiatry 156:286-93. 1999
    ..The purpose of this study was to compare the D2 and serotonin 5-HT2 receptor occupancies of these drugs in patients receiving multiple-dose, steady-state regimens...
  26. ncbi request reprint D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET
    G Remington
    Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Ontario, Canada
    J Clin Psychiatry 60:15-9. 1999
    ..Combined serotonin-2/dopamine-2 (5-HT2/D2) antagonism represents one such model, and we now have PET evidence available that can be extrapolated to our understanding and clinical use of both conventional and novel antipsychotics...
  27. ncbi request reprint Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine
    S Kapur
    PET Centre, Clarke Division, CAMH, Toronto, ONT Canada
    Am J Psychiatry 158:311-4. 2001
    ....
  28. doi request reprint Association study of cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia
    A K Tiwari
    Neurogenetics Section, Neuroscience Department, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Pharmacogenomics J 12:260-6. 2012
    ..These results indicate a possible role of CNR1 in the development of TD in our patient population. However, these observations are marginal after correcting for multiple testing and need to be replicated in a larger patient population...
  29. doi request reprint Prediction of longitudinal functional outcomes in schizophrenia: the impact of baseline motivational deficits
    G Foussias
    Centre for Addiction and Mental Health, and Department of Psychiatry, University of Toronto, 250 College St, Toronto, Ontario, Canada M5T 1R8
    Schizophr Res 132:24-7. 2011
    ..These findings further suggest a fundamental role for motivational deficits in predicting functional outcomes in schizophrenia...
  30. ncbi request reprint Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient
    S Kapur
    Schizophrenia Program, University of Toronto, Toronto, Canada
    Biol Psychiatry 50:873-83. 2001
    ....
  31. ncbi request reprint Pharmacotherapy of first-episode schizophrenia
    G Remington
    Department of Psychiatry, University of Toronto, Canada
    Br J Psychiatry Suppl 172:66-70. 1998
    ..A growing interest in first-episode schizophrenia reflects the belief that this line of investigation will lead to further developments regarding schizophrenia's aetiology, course and outcome...
  32. ncbi request reprint Are animal studies of antipsychotics appropriately dosed? Lessons from the bedside to the bench
    S Kapur
    PET Centre, Centre for Addiction and Mental Health, Toronto, ON
    Can J Psychiatry 45:241-6. 2000
    ..We exemplify how this dosing confounder could lead to inappropriate conclusions. Data from the bedside translated to the bench--using D2 occupancy as a mediating variable--will lead to more valid animal models...
  33. ncbi request reprint Health care utilization in patients with schizophrenia maintained on atypical versus conventional antipsychotics
    G Remington
    Schizophrenia and Continuing Care Program, Clarke Division, Centre for Addiction and Mental Health, University of Toronto, Ontario, Canada
    Prog Neuropsychopharmacol Biol Psychiatry 25:363-9. 2001
    ....
  34. ncbi request reprint Atypical antipsychotics: are some more atypical than others?
    G Remington
    Schizophrenia Program, Centre for Addiction and Mental Health, Clarke Division, 250 College Street, Toronto, Ontario, Canada M5T 1R8
    Psychopharmacology (Berl) 148:3-15. 2000
    ..The precise pharmacologic mechanisms underlying "atypicality" remain unclear, but several conceptual frameworks are highlighted that characterize, and perhaps differentiate, these newer agents...
  35. pmc Conventional versus novel antipsychotics: changing concepts and clinical implications
    G Remington
    Clarke Institute of Psychiatry, University of Toronto, Ont
    J Psychiatry Neurosci 24:431-41. 1999
    ..Future research should involve longer clinical trials, given the long periods needed to establish efficacy, and should address many remaining questions about the novel agents...
  36. ncbi request reprint Significant dissociation of brain and plasma kinetics with antipsychotics
    Johannes Tauscher
    Schizophrenia PET program, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada
    Mol Psychiatry 7:317-21. 2002
    ..Our results question the current reliance on plasma kinetics as the main basis for dosing regimens of antipsychotics. Studies of brain kinetics may provide a sounder basis for determining dosing schedules of psychotropic medications...
  37. doi request reprint Motivational deficits as the central link to functioning in schizophrenia: a pilot study
    G Foussias
    Department of Psychiatry, University of Toronto, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Schizophr Res 115:333-7. 2009
    ..This suggests that motivational deficits are the central link between negative symptoms and functional impairment in schizophrenia...
  38. doi request reprint Examining cognitive biases in patients with delusions of reference
    M Menon
    Schizophrenia Program and PET Centre, Centre for Addiction and Mental Health, 250 College St, Toronto M5T 1R8, Canada
    Eur Psychiatry 28:71-3. 2013
    ..A sample of patients with delusions of reference did not show the jumping to conclusions (JTC) bias. JTC appears to be more closely related to paranoia than referential delusions...
  39. ncbi request reprint Haloperidol and loxapine but not clozapine increase synaptic responses in the hippocampus
    A Baskys
    Department of Physiology, University of Toronto, Ont, Canada
    Eur J Pharmacol 235:305-7. 1993
    ..These data suggest that haloperidol and loxapine may act by enhancing excitatory synaptic transmission in some areas of the brain, and that novel antipsychotic clozapine differs in its mechanism of action...
  40. doi request reprint Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients
    C C Zai
    Neurogenetics Section, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Pharmacogenomics J 9:168-74. 2009
    ..This study suggests that DRD4 may be involved in TD in the Caucasian population, although further replication studies are needed...
  41. ncbi request reprint Simultaneous quantitation of loxapine, amoxapine and their 7- and 8-hydroxy metabolites in plasma by high-performance liquid chromatography
    S W Cheung
    Psychopharmacology Unit, Clarke Institute of Psychiatry, Toronto, Canada
    J Chromatogr 564:213-21. 1991
    ..As 8-hydroxy metabolites possess only weak dopamine-D2 blocking activity, the final neuroleptic property of loxapine may be affected significantly by metabolic polymorphism...
  42. ncbi request reprint Hyperinsulinemia in psychiatric patients treated with olanzapine
    Tony A Cohn
    J Clin Psychiatry 63:75-6. 2002
  43. ncbi request reprint Differential effects of within-day continuous vs. transient dopamine D2 receptor occupancy in the development of vacuous chewing movements (VCMs) in rats
    Peter Turrone
    Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada
    Neuropsychopharmacology 28:1433-9. 2003
    ..These findings support the contention that D(2) occupancy levels induced by chronic HAL must be high and sustained through the day before significant risk of VCMs, and perhaps also TD, emerges...
  44. ncbi request reprint The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats
    Peter Turrone
    Centre for Addiction and Mental Health, Schizophrenia and Continuing Care Program, 250 College Street, Room 745, Toronto, Ontario, Canada M5T 1R8
    Psychopharmacology (Berl) 165:166-71. 2003
    ..A dose-response relationship between dopamine D(2) occupancy and acute extrapyramidal symptoms (EPS) has been well established. However, the link with the induction of tardive dyskinesia (TD) is less clear...
  45. ncbi request reprint How much are atypical antipsychotic agents being used, and do they reach the populations who need them? A Canadian experience
    Carolyn S Dewa
    Health Systems Research and Consulting Unit, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Clin Ther 24:1466-76. 2002
    ..The introduction of new antipsychotic agents in the past decade has helped alter the treatments available to 2 vulnerable populations-those with schizophrenia and related psychotic conditions and elderly individuals with dementia...
  46. ncbi request reprint Early use of clozapine for poorly responding first-episode psychosis
    Ofer Agid
    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    J Clin Psychopharmacol 27:369-73. 2007
    ....
  47. ncbi request reprint Clozapine-induced hypersalivation: a review of treatment strategies
    Sanjeev Sockalingam
    Department of Psychiatry, University of Toronto, Ontario
    Can J Psychiatry 52:377-84. 2007
    ..The purpose of this review is to provide an understanding of CIH, specifically, its pathophysiology, measurement, and the evidence for CIH treatment alternatives...
  48. doi request reprint Adjunctive versus monotherapeutic treatment for schizophrenia: addressing antipsychotic side effects
    Monica Hazra
    Am J Psychiatry 165:396-7; author reply 397-8. 2008
  49. ncbi request reprint Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia
    Hiroyuki Uchida
    Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    J Clin Psychiatry 69:1281-6. 2008
    ..The objective of this positron emission tomography (PET) study was to examine the striatal dopamine D(2) binding of long-acting risperidone administered intramuscularly once a month...
  50. ncbi request reprint Emerging drugs for schizophrenia
    Ofer Agid
    Centre for Addiction and Mental Health, Schizophrenia Program, Department of Psychiatry, University of Toronto, 250 College Street, Toronto, Ontario M5T 1R8, Canada
    Expert Opin Emerg Drugs 13:479-95. 2008
    ..As the dust settles on this period and substantial data, as well as practical prescribing experience, are available, we examine what has been gained and what can be learned...
  51. ncbi request reprint The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D(2) receptor occupancy?
    Peter Turrone
    Institute of Medical Science, University of Toronto, Toronto, Ont, Canada
    Neurosci Biobehav Rev 26:361-80. 2002
    ..These findings are consistent with the possibility that total D(2) occupancy, as well as 'transience' of receptor occupation, may be important in the development of late-onset antipsychotic-induced dyskinetic syndromes...
  52. pmc Interventions to reduce weight gain in schizophrenia
    Guy Faulkner
    Faculty of Physical Education and Health, University of Toronto, Toronto, Canada
    Schizophr Bull 33:654-6. 2007
  53. ncbi request reprint Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats
    Peter Turrone
    Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada
    Biol Psychiatry 57:406-11. 2005
    ..The objective of this study was to determine whether continuous, versus intermittent, olanzapine (OLZ) infusion differently affects the development of VCMs...
  54. ncbi request reprint Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia
    Donald Addington
    Departments of Psychiatry, University of Calgary, Calgary, Alberta, Canada
    J Clin Psychopharmacol 22:20-5. 2002
    ..Testing the efficacy of widely accepted but poorly evaluated treatments should be a research priority. Future studies require a larger sample size and longer duration of treatment...
  55. ncbi request reprint Body mass index, waist circumference and quality of life in individuals with schizophrenia
    Guy Faulkner
    Faculty of Physical Education and Health, University of Toronto, Ontario, Canada M5S 2W6
    Schizophr Res 90:174-8. 2007
    ..The primary objective was to examine the differential relationship between waist circumference, body mass index, and self-reported quality of life in patients with schizophrenia...
  56. ncbi request reprint Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients
    Clement C Zai
    Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Int J Neuropsychopharmacol 10:639-51. 2007
    ..047). Taken together, the present study suggests that DRD2 may be involved in TD in the Caucasian population, although further studies are warranted...
  57. ncbi request reprint Effect of acute antipsychotic administration on dopamine synthesis in rodents and human subjects using 6-[18F]-L-m-tyrosine
    David Mamo
    Department of Psychiatry, University of Toronto, Canada
    Synapse 52:153-62. 2004
    ..Our results suggest that 6-[18F]-L-m-tyrosine PET may not be a useful tool in the study of the effect of antipsychotics on dopamine synthesis in human subjects...
  58. ncbi request reprint Predictors and markers of clozapine response
    Carmen Chung
    Centre for Addiction and Mental Health, Schizophrenia Program, 250 College Street, Toronto, Ontario, M5T 1R8, Canada
    Psychopharmacology (Berl) 179:317-35. 2005
    ..With other atypical antipsychotics now available, having predictors of clozapine response would be of considerable value, offering clinicians guidance in their decision as to when, and if, a trial of clozapine is warranted...
  59. ncbi request reprint Direct activation of the ventral striatum in anticipation of aversive stimuli
    Jimmy Jensen
    PET Centre, Centre for Addiction and Mental Health, Baycrest Geriatric Centre, Toronto, Ontario, Canada
    Neuron 40:1251-7. 2003
    ..Our data suggest that the ventral striatum, a crucial element of the brain "reward" system, is directly activated in anticipation of aversive stimuli...
  60. ncbi request reprint Association study between a functional glutathione S-transferase (GSTP1) gene polymorphism (Ile105Val) and tardive dyskinesia
    Takahiro Shinkai
    Neurogenetics Section, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Ont, Canada M5T 1R8
    Neurosci Lett 388:116-20. 2005
    ..1, p=1.00) were observed between subjects with and without TD. Our results suggest that the GSTP1 gene polymorphism does not confer increased susceptibility to TD, although further studies are warranted before a conclusion can be drawn...
  61. ncbi request reprint Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic
    W Wolfgang Fleischhacker
    Department of Biological Psychiatry, Innsbruck University Clinics, Anichstrasse 35, 6020 Innsbruck, Austria
    J Clin Psychiatry 64:1250-7. 2003
    ..The long-term safety and efficacy of long-acting injectable risperidone, the first long-acting second-generation antipsychotic, were evaluated in stable patients with schizophrenia...
  62. ncbi request reprint Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics
    Johannes Tauscher
    University of Toronto Department of Psychiatry, Schizophrenia Program
    Am J Psychiatry 161:1620-5. 2004
    ....
  63. ncbi request reprint Psychometric evaluation of the Readiness for Discharge Questionnaire
    Steven G Potkin
    University of California, Irvine, Department of Psychiatry and Human Behavior, Brain Imaging Center, Irvine Hall, Room 166, Orange, CA, USA
    Schizophr Res 80:203-12. 2005
    ..The psychometric properties of the RDQ are described...
  64. pmc Actigraphic measurement of the effects of single-dose haloperidol and olanzapine on spontaneous motor activity in normal subjects
    Michael Kiang
    Schizophrenia Division, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, Ont
    J Psychiatry Neurosci 28:293-9. 2003
    ..To quantitatively examine the effects of haloperidol and olanzapine on spontaneous motor activity in normal subjects...
  65. ncbi request reprint "Extended" antipsychotic dosing: rationale and pilot data
    Gary Remington
    J Clin Psychopharmacol 25:611-3. 2005
  66. ncbi request reprint A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone
    David Mamo
    Department of Psychiatry, University of Toronto, Montreal, Canada
    Am J Psychiatry 161:818-25. 2004
    ..The affinity of ziprasidone for these receptors in vivo in patients was examined in a positron emission tomography (PET) study...
  67. ncbi request reprint Tardive dyskinesia and iron status
    Siow Ann Chong
    J Clin Psychopharmacol 24:235-6. 2004
  68. ncbi request reprint Augmenting strategies in clozapine-resistant schizophrenia
    Gary Remington
    CNS Drugs 20:171. 2006
  69. ncbi request reprint Apathy in schizophrenia: clinical correlates and association with functional outcome
    Michael Kiang
    Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Schizophr Res 63:79-88. 2003
    ..It was not associated with observed interest in playing a video game or performance on a simulated clerical task...
  70. ncbi request reprint Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood
    Huma Saeedi
    Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Schizophr Res 85:222-31. 2006
    ..The present results suggest that DA D(2) blockade, as induced by haloperidol, produces important deficits that extend beyond motor or endocrine changes...
  71. ncbi request reprint Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: A preliminary report
    Tony A Cohn
    Department of Psychiatry, Faculty of Medicine, University of Toronto, Ontario
    Can J Psychiatry 51:382-6. 2006
    ..To compare the insulin sensitivity and adiponectin levels of medication-free patients suffering from schizophrenia or schizoaffective disorder with that of matched healthy volunteers...
  72. ncbi request reprint Schizophrenia, antipsychotics, and the metabolic syndrome: is there a silver lining?
    Gary Remington
    Am J Psychiatry 163:1132-4. 2006
  73. ncbi request reprint Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome
    Tony Cohn
    Department of Psychiatry, University of Toronto, and Center for Addiction and Mental Health, Toronto, Ontario
    Can J Psychiatry 49:753-60. 2004
    ..To determine the prevalence and characteristics of coronary heart disease (CHD) risk factors in patients with chronic schizophrenia or schizoaffective disorder...
  74. ncbi request reprint Overstating the case about recovery?
    Gary Remington
    Psychiatr Serv 56:1022; author reply 1022-3. 2005
  75. ncbi request reprint Remission: what's in a name?
    Gary Remington
    Am J Psychiatry 162:2393-4; author reply 2394. 2005
  76. ncbi request reprint Validation of a physical activity assessment tool for individuals with schizophrenia
    Guy Faulkner
    Faculty of Physical Education and Health, University of Toronto, 55 Harbord Street, Toronto, Ontario, Canada M5S 2W6
    Schizophr Res 82:225-31. 2006
    ..The objective of this study was to provide preliminary validation of the Short-Form International Physical Activity Questionnaire (IPAQ), a measurement tool that could prove useful for both clinicians and researchers in the field...
  77. ncbi request reprint Use of atypical antipsychotics during pregnancy and the risk of neural tube defects in infants
    Gideon Koren
    Division of Clinical Pharmacology Toxicology, The Hospital for Sick Children, Toronto, Ont, Canada
    Am J Psychiatry 159:136-7. 2002
    ..Atypical antipsychotics cause various degrees of weight gain. The authors assessed folate status and obesity among patients with schizophrenia receiving atypical antipsychotics...